Nascent Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023

Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a drug candidate, Pritumumab, which the Company is developing as a treatment for epithelial cancers that includes lung, breast, colon, brain, and pancreas. Its initial focus is on patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. The Company is exploring Pritumumab in its use against viruses. The Company is also engaged in developing a traditional vaccine platform to create vaccines for viral infections.